Transmedics Group Inc(TMDX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 5:11 PM ET (Korea 9/12 06:11)
Full metrics table
| Index | RUT | P/E | 21.38 | EPS (ttm) | 3.84 | Insider Own | 3.86% | Shs Outstand | 34.6M | Perf Week | -5.52% |
| Market Cap | 2.85B | Forward P/E | 35.73 | EPS next Y | 55.05% | Insider Trans | -0.71% | Shs Float | 33.3M | Perf Month | -5.56% |
| Enterprise Value | 3.24B | PEG | - | EPS next Q | 0.3 | Inst Own | 102.04% | Short Float | 24.23% | Perf Quarter | 11.67% |
| Income | 0.15B | P/S | 4.26 | EPS this Y | -69.54% | Inst Trans | -5.02% | Short Ratio | 8.88 | Perf Half Y | -32.26% |
| Sales | 0.67B | P/B | 5.49 | EPS next 5Y | -12.77% | ROA | 12.88% | Short Interest | 8.08M | Perf YTD | -32.45% |
| Book/sh | 14.96 | P/C | 6.03 | EPS past 3/5Y | - | ROE | 36.28% | 52W High | -47.32% ($156.00) | Perf Year | -29.75% |
| Cash/sh | 13.63 | P/FCF | 36.05 | Sales past 3/5Y | 86.42% 88.21% | ROIC | 11.14% | 52W Low | 36.73% ($60.10) | Perf 3Y | 38.05% |
| Dividend Est. | - | EV/EBITDA | 27.49 | EPS Y/Y TTM | 108.84% | Gross Margin | 57.75% | Volatility(W/M) | 4.63% 4.2% | Perf 5Y | 158.92% |
| Dividend TTM | - | EV/Sales | 4.85 | Sales Y/Y TTM | 25.82% | Oper. Margin | 12.21% | ATR (14) | 4.3 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.07 | EPS Q/Q | -55.84% | Profit Margin | 22.69% | RSI (14) | 43.51 | Recom | 1.75 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.62 | Sales Q/Q | 20.7% | SMA20 | -7.51% ($88.85) | Beta | 1.92 | Target Price | $97.3 |
| Payout | - | Debt/Eq | 1.67 | Earnings | 2026/8/4 | SMA50 | 0.74% ($81.58) | Rel Volume | 1.31 | Prev Close | $85.04 |
| Employees | 898 | LT Debt/Eq | 1.63 | EPS/Sales Surpr. | -11.2% 3.23% | SMA200 | -20.94% ($103.95) | Avg Volume(3M) | 0.91M | Price | $82.18 |
| IPO | 2019/5/2 | Option/Short | Yes/Yes | Trades | 17006 | Volume | 1,191,737 | Change | -3.36% |
Company
TMDX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🫀 This US medical device company develops organ preservation and transport technology for long-term transplantation. Rather than storing donated organs in cold storage, its innovative system preserves and transports them in a living, functioning state, increasing the utilization of livers, hearts, and lungs for transplantation. The company offers an integrated transplant solution that combines organ preservation equipment, consumables, and a transport logistics network.
Over the past 1 year, on the lower side
47% below its 1-year high.
TMDX makes money exceptionally well
12.21% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -69.5% this year.
Tap to view numbers
The price looks about right
Trading at 21.4 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +38.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 102.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
RKNG 0.03%
LFSC 0.03%
HEAL 0.02%
CSMD 0.02%
ULTY 0.02%It ranks #4 in the industry
Based on market cap of $3B.
TMDX $3B PER 21.4
ABT $176B PER 33.0
MDT $116B PER 22.4
SYK $106B PER 28.6
FAQ
What kind of company is TMDX?
TMDX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TMDX?
The market cap of TMDX is approximately $2.8B, ranking 1,823 within its sector.
What is the P/E ratio of TMDX?
TMDX has a P/E ratio of approximately 21.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for TMDX?
TMDX has recorded a 52-week high of $156.00 and a low of $60.10.
